Skip to main content
. Author manuscript; available in PMC: 2015 Apr 10.
Published in final edited form as: Int J Pharm. 2014 Jan 17;464(0):178–184. doi: 10.1016/j.ijpharm.2014.01.009

Figure 6.

Figure 6

Tumor inhibition studies with various micellar formulations. Nude mice bearing ~200 mm3 SK-OV-3 (A) and SK-OV-3TR (B) tumors were treated every 3 days at a dose of 25 mg/kg CUR and 10 mg/kg PCL IP starting at day zero. Empty micelle dose was equivalent to the amount of micelle-forming material from the drug-loaded micelle groups. (One way ANOVA was performed from day 45–75 on A and from day 30–60 on B, * p<0.05 with n ≥5 /group and all values are expressed as mean ± SEM. SK-OV-3 (C) and SK-OV-3TR (D) tumors were harvested when the average tumor volume in the control group reached 1000 mm3. (Student’s two tailed unpaired T-test, * p<0.05) n ≥5/group ± SEM.